Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04EYC
|
||||
| Former ID |
DAP000225
|
||||
| Drug Name |
Metaraminol
|
||||
| Synonyms |
Araminol; Hydroxynorephedrine; Isophenylephrine; Metaradrin; Metaradrine; Metaraminolum; Pressonex; Pressorol; Icoral B; Metaraminolum [Latin]; Aramine (TN); L-Metaraminol; M-Hydroxy norephedrine; M-Hydroxynorephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; Meta-Hydroxynorephedrine; Metaraminol (INN); Metaraminol [INN:BAN]; Metaraminolum [INN-Latin]; Alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; Alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Alpha-(m-Hydroxyphenyl)-beta-aminopropanol; M-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-(9CI); (-)-Erythro-metaraminol; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 1-Metaraminol; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; 3-Hydroxyphenylisopropanolamine; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypotension [ICD9: 458, 796.3; ICD10:I95] | Approved | [1], [2] | ||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Company |
Merck Sharp & Dohme Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H13NO2
|
||||
| InChI |
InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1
|
||||
| InChIKey |
WXFIGDLSSYIKKV-RCOVLWMOSA-N
|
||||
| CAS Number |
CAS 54-49-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9355, 7979912, 8153659, 15219458, 29224933, 46505593, 48416227, 49698383, 49892583, 50122612, 50122613, 51071119, 53801146, 57323039, 96024882, 104310584, 124955682, 132559968, 134222988, 134337540, 135269866, 135866973, 137001302, 141079008, 160963955, 178103803, 179316238, 184547031, 198942357, 226504333, 252351591
|
||||
| ChEBI ID |
ChEBI:6794
|
||||
| SuperDrug ATC ID |
C01CA09
|
||||
| SuperDrug CAS ID |
cas=000054499
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080722. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7229). | ||||
| REF 3 | Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.